La vendita allo scoperto per Lifevantage dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Lifevantage. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Lifevantage (NASDAQ:LFVN) Azioni, Report sulle vendite allo scoperto

Lifevantage

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Lifevantage Corp

Disclosed in the latest SEC filing, a significant insider purchase on November 12, involves Darwin Lewis, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>).
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000132//Archives/edgar/data/849146/000084914624000132/0000849146-24-000132-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled that Lewis made a notable purchase of 7,819 shares of Lifevantage, valuing at $105,009.
Lifevantage shares are trading up 0.29% at $13.78 at the time of this writing on Wednesday morning.
<h3>Delving into Lifevantage's Background</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Breaking Down Lifevantage's Financial Performance</h3>
Revenue Challenges: Lifevantage's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.08%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a high gross margin of 79.9%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.91, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio, surpassing industry averages at 17.77, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

LFVN

Massive Insider Trade At Lifevantage

In a recent SEC filing, it was revealed that Garry P. Mauro, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), made a noteworthy insider purchase on November 12,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000133//Archives/edgar/data/849146/000084914624000133/0000849146-24-000133-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Mauro purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
The latest update on Wednesday morning shows Lifevantage shares up by 0.29%, trading at $13.78.
<h3>Delving into Lifevantage's Background</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Breaking Down Lifevantage's Financial Performance</h3>
Revenue Growth: Lifevantage's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -8.08%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 79.9%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.91 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 17.77, Lifevantage demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of Lifevantage Makes $105K Buy

On November 12, Rajendran Anbalagan, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000134//Archives/edgar/data/849146/000084914624000134/0000849146-24-000134-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Anbalagan purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
As of Wednesday morning, Lifevantage shares are up by 0.29%, currently priced at $13.78.
<h3>Unveiling the Story Behind Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: Financial Performance Dissected</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 79.9%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 42.94 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.91 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 17.77, Lifevantage demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: Rajendran Anbalagan Shows Faith, Buying $105K In Lifevantage Stock

It was revealed in a recent SEC filing that Michael Beindorff, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) made a noteworthy insider purchase on November 12,.
What Happened: Beindorff demonstrated confidence in Lifevantage by purchasing 7,819 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000135//Archives/edgar/data/849146/000084914624000135/0000849146-24-000135-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the transaction is $105,009.
The latest market snapshot at Wednesday morning reveals Lifevantage shares up by 0.29%, trading at $13.78.
<h3>All You Need to Know About Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Key Indicators: Lifevantage's Financial Health</h3>
Decline in Revenue: Over the 3 months period, Lifevantage faced challenges, resulting in a decline of approximately -8.08% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 79.9%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Lifevantage exhibits below-average bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 42.94 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.91 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio stands at 17.77, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Board Member Makes $105K Stock Purchase

Dayton Judd, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported an insider buy on November 12, according to a new SEC filing. 
What Happened: Judd's recent purchase of 7,819 shares of Lifevantage, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000136//Archives/edgar/data/849146/000084914624000136/0000849146-24-000136-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, reflects confidence in the company's potential. The total transaction value is $105,009.
The latest market snapshot at Wednesday morning reveals Lifevantage shares up by 0.29%, trading at $13.78.
<h3>All You Need to Know About Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: A Financial Overview</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: Lifevantage's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 42.94 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.91, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio stands at 17.77, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dayton Judd Of Lifevantage Shows Optimism, Buys $105K In Stock

It was revealed in a recent SEC filing that Raymond B Greer, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) made a noteworthy insider purchase on November 12,.
What Happened: Greer's recent purchase of 7,819 shares of Lifevantage, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000137//Archives/edgar/data/849146/000084914624000137/0000849146-24-000137-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, reflects confidence in the company's potential. The total transaction value is $105,009.
Monitoring the market, Lifevantage's shares up by 0.29% at $13.78 during Wednesday's morning.
<h3>Unveiling the Story Behind Lifevantage</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage's Economic Impact: An Analysis</h3>
Revenue Challenges: Lifevantage's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -8.08%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 79.9%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.15.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: Lifevantage's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 42.94.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.91 is lower than the industry average, implying a discounted valuation for Lifevantage's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lifevantage's EV/EBITDA ratio, surpassing industry averages at 17.77, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: Raymond B Greer Shows Faith, Buying $105K In Lifevantage Stock

On November 12, a substantial insider purchase was made by Cynthia Latham, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914624000138//Archives/edgar/data/849146/000084914624000138/0000849146-24-000138-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Latham purchased 7,819 shares of Lifevantage. The total transaction amounted to $105,009. 
During Wednesday's morning session, Lifevantage shares up by 0.29%, currently priced at $13.78.
<h3>Discovering Lifevantage: A Closer Look</h3>
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
<h3>Lifevantage: Financial Performance Dissected</h3>
Negative Revenue Trend: Examining Lifevantage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -8.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 79.9%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lifevantage's EPS is below the industry average. The company faced challenges with a current EPS of 0.15. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.48, Lifevantage adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 42.94, Lifevantage's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.91, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 17.77, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

105K Reasons To Be Bullish On Lifevantage Stock

WIIM

Lifevantage shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) affirms FY2025 Adj EPS guidance from $0.70-0.80 to $0.70-0.80 vs $0.72 analyst estimate. Affirms FY2025 sales outlook from $200.00 million-210.00 million to $200.00 million-210.00 million vs $204.80 million estimate.

Guidance

Lifevantage Affirms FY2025 Adj EPS Guidance from $0.70-0.80 to $0.70-0.80 vs $0.72 Est; Affirms FY2025 Sales Guidance from $200.00M-210.00M to $200.00M-210.00M vs $204.80M Est

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 15.38 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $47.214 million which missed the analyst consensus estimate of $49.800 million by 5.19 percent. This is a 8.08 percent decrease over sales of $51.364 million the same period last year.

Earnings

Earnings Misses

Lifevantage Q1 2025 Adj. EPS $0.15, Inline, Sales $47.214M Miss $49.800M Estimate

LifeVantage Corporation Released Encouraging Results From A Human Clinical Trial On Its New MindBody GLP-1 System. The Results Included A 140% Increase In GLP-1 Levels In The Body Leading To An Average Weight Loss of 9 Pounds In 8 Weeks And Up To 25 Pounds In 12 Weeks

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-10-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Lifevantage will report an earnings per share (EPS) of $0.15.
Anticipation surrounds Lifevantage's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.07, leading to a 11.8% drop in the share price on the subsequent day.
Here's a look at Lifevantage's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.16</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
<td>0.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-12.0%</td>
<td>8.0%</td>
<td>-9.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking Lifevantage's Stock Performance</h3>
Shares of Lifevantage were trading at $14.09 as of October 25. Over the last 52-week period, shares are up 83.87%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LFVN/earnings">To track all earnings releases for Lifevantage visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Lifevantage's Earnings

<h3>Gainers</h3>
<ul>
<li>Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) stock increased by 214.4% to $9.43 during Friday's regular session. The company's market cap stands at $9.8 million. </li>
<li>Rocky Mountain Chocolate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCF#NASDAQ">RMCF</a>) stock rose 17.14% to $3.25. The company's market cap stands at $24.6 million. </li>
<li>China Jo-Jo Drugstores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJJD#NASDAQ">CJJD</a>) shares increased by 17.12% to $2.15. The market value of their outstanding shares is at $14.3 million. </li>
<li>Elevai Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) stock increased by 15.13% to $0.11. The company's market cap stands at $5.2 million. </li>
<li>S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) shares rose 10.63% to $2.6. The market value of their outstanding shares is at $5.9 million. </li>
<li>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) shares moved upwards by 9.39% to $14.2. The market value of their outstanding shares is at $177.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Top Wealth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) stock declined by 83.6% to $2.21 during Friday's regular session. The market value of their outstanding shares is at $123.7 million. </li>
<li>Blue Star Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) shares declined by 18.42% to $0.42. The market value of their outstanding shares is at $1.0 million. </li>
<li>Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) stock declined by 15.96% to $2.95. The market value of their outstanding shares is at $16.9 million. </li>
<li>Farmmi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) shares declined by 14.63% to $0.41. The market value of their outstanding shares is at $4.3 million. </li>
<li>Fresh Vine Wine (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VINE#AMEX">VINE</a>) stock declined by 14.6% to $0.91. The market value of their outstanding shares is at $14.4 million. </li>
<li>Nuzee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) shares declined by 10.75% to $0.95. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BSFC

CJJD

ELAB

FAMI

NUZE

RMCF

SANW

SDOT

UPXI

VINE

12 Consumer Staples Stocks Moving In Friday's Intraday Session

JSPR: 32% &#x7C; <a href="https://www.benzinga.com//node/41310862">Jasper Therapeutics shares are trading higher after the company announced it reported preliminary data from the Company's ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism.</a>
&nbsp;
LFVN: 11% &#x7C; <a href="https://www.benzinga.com//node/41311255">LifeVantage shares are trading higher after the company announced the US launch of its MindBody GLP-1 System.</a>
&nbsp;
IVA: 177% &#x7C; <a href="https://www.benzinga.com//node/41307848">Inventiva Raises Up To €348M To Fund Phase 3 NATiV3 Clinical Trial For MASH, Appoints New Chairman and Director</a>
&nbsp;
&nbsp;

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Market-Moving News for October 14th

Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger Hormones and Reduce Cravings, Supporting Sustainable Weight and Visceral Fat Loss While Maintaining Muscle ‡Ω &nbsp;
SALT LAKE CITY, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=nzT520nlQLahRAI0Hd8RtObUXAukr7RPvtLN8FJ35Tv7Q3qWUfZcIxxEIC22qXL-7xweImjGYffSYSFz-vUxyUH2XqP1JjRI495NKRG2aC3ia54C6SV8ad3QdUj2Lu0IXmsscru1gVAV_mfk494E8yBJJZ2vkw2TF_Qn8tsXtpE9RKplZdzN5YGsFHnWkYo02UnnQxjroArp7ARq9_P21w==">LifeVantage Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is excited to announce the U.S. launch of its patent-pending MindBody GLP-1 System&#x2122;, a dual-product solution designed to balance hunger hormones, build healthier habits, and help individuals reach and maintain their ideal weight. This revolutionary system includes MB Core&#x2122; and MB Enhance&#x2122;, which work together to activate natural GLP-1 production by 140% on average. Clinical trials also found that the new System helped participants lose up to 27% of visceral fat and 5% of total body fat while maintaining muscle. &#x2A;‡Ω
The new System was revealed at Market Connect held October 11-12, in Kansas City. Event attendees sold out on-site product within hours and additional inventory was brought in to meet the high demand. Demand was apparent across the market as well, with e-commerce sales also exceeding forecast.

Biotech

General

LifeVantage Introduces The MindBody GLP-1 System, The Dual-Product System Is Clinically Shown To Increase GLP-1 By 140% On Average To Balance Hunger Hormones And Reduce Cravings, Supporting Sustainable Weight And Visceral Fat Loss While Maintaining Muscle

LifeVantage shares are trading higher after the company announced the US launch of its MindBody GLP-1 System.

<h3>Gainers</h3>
<ul>
<li>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) shares rose 7.0% to $13.0 during Monday's pre-market session. The market value of their outstanding shares is at $162.2 million. </li>
<li>Big Tree Cloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares rose 6.55% to $3.9. The market value of their outstanding shares is at $222.6 million. </li>
<li>Fresh Vine Wine (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VINE#AMEX">VINE</a>) stock increased by 5.51% to $0.89. The company's market cap stands at $14.2 million. </li>
<li>Nuzee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) stock moved upwards by 5.27% to $0.42. The market value of their outstanding shares is at $2.0 million. </li>
<li>DDC Enterprise (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DDC#AMEX">DDC</a>) stock rose 5.08% to $0.31. The market value of their outstanding shares is at $6.9 million. </li>
<li>AgriFORCE Growing Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) shares moved upwards by 4.81% to $0.06. The market value of their outstanding shares is at $5.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Top Wealth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares fell 26.5% to $5.25 during Monday's pre-market session. The company's market cap stands at $152.2 million. </li>
<li>Innovation Beverage Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares fell 20.0% to $0.8. The company's market cap stands at $6.6 million. </li>
<li>Farmmi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) stock declined by 9.9% to $0.25. The company's market cap stands at $2.6 million. </li>
<li>Blue Star Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) shares fell 3.7% to $0.47. The market value of their outstanding shares is at $1.1 million. </li>
<li>Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) stock declined by 3.46% to $3.63. The company's market cap stands at $382.3 million. </li>
<li>HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) stock fell 3.44% to $3.37. The company's market cap stands at $177.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRI

HFFG

12 Consumer Staples Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) shares moved upwards by 7.7% to $0.37 during Thursday's after-market session. The company's market cap stands at $16.8 million. </li>
<li>Branchout Food (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) stock rose 7.44% to $1.56. The market value of their outstanding shares is at $10.7 million. </li>
<li>Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) shares rose 3.55% to $1.16. The market value of their outstanding shares is at $70.0 million. </li>
<li>S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) stock rose 3.51% to $0.23. The company's market cap stands at $9.9 million. </li>
<li>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) shares increased by 2.89% to $11.74. The company's market cap stands at $146.5 million. </li>
<li>Maison Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) shares rose 2.43% to $1.25. The market value of their outstanding shares is at $24.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevai Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares decreased by 16.7% to $0.11 during Thursday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>Big Tree Cloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares declined by 6.93% to $3.63. The market value of their outstanding shares is at $207.2 million. </li>
<li>Guardion Health Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHSI#NASDAQ">GHSI</a>) stock declined by 4.86% to $3.33. The market value of their outstanding shares is at $4.2 million. </li>
<li>Shineco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) shares fell 3.81% to $0.23. The market value of their outstanding shares is at $7.1 million. </li>
<li>DDC Enterprise (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DDC#AMEX">DDC</a>) shares declined by 2.66% to $0.3. The market value of their outstanding shares is at $6.7 million. </li>
<li>Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) stock fell 2.57% to $1.52. The market value of their outstanding shares is at $20.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLGC

GHSI

Merrill Lynch & Strategic Return Notes for Select 10 Index

SHOT

SISI

12 Consumer Staples Stocks Moving In Thursday's After-Market Session

<a href="https://www.globenewswire.com/Tracker?data=73iuP2pGxIP0aRYuMzQ_Nxow3ClU9NqbZhMgciGwar9x-EPZhCftrOxkEzBeY8tlM1RsVDgmWZWnUmStoDZQzhGPtEZgMYWJBZUl6AHga786wb4N6Yn4GTO_KISv3-kdmsKtW2zDTI_z_aET8v4Yomim-iukd64JxRGjGh7DfvGP_Hr9jzUVBnHXzzMMocAtga9OQkHLB_iibTUxKdUc4TkQ8tD7Icm2NtnmrWFJ4FeJOVcNU3UAwZXP7aYbEbQn--k9x5M38WbSVjP_aMHWnQO7ggyvWusmE0DIg_xcore0Z6SDFKppTv08k7WJXmgVyLBtWn16moXoXKsPjTj6iIZpqGtnnCgI27A125cwQAtpSNtxmt3k5xLgEh0AR-bxhRydfBjD7dYo77vfX5--jKduee8eUrb_QiKQ0ZzP9v8fytJZ2Yh0Ww76BVjULlhPw5JT14KcKffIkeCrGGATALTbicZu4SnPeaFroiU086ipv0ivq6ZE324YFfaC5tgwD51gM_FqmulX6QDRq13f7XPg8to1jRpe6RjBwrcYFpQaMFFnIyyhkmCQC9sRKaYnBYh68LziZ3H_mCBYsvJ9Sw==">LifeVantage Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced an enhancement to its Evolve Compensation Plan, offering greater simplicity and earning potential for independent LifeVantage Consultants. Plan enhancements are set to go live November 1, 2024, in the U.S., Japan, Australia, New Zealand, Canada, Mexico, and European markets.

Global

LifeVantage Announces Update To Evolve Compensation Plan With New Sharing Bonus; Plan Enhancements Are Set To Go Live November 1, 2024, In The U.s., Japan, Australia, New Zealand, Canada, Mexico, And European Markets

LifeVantage shares are trading higher after the company announced the completion of a successful 12-week clinical trial for its new GLP-1 system for weight loss.

Multi-Level Marketing: Stagnation Or Something Worse?

LifeVantage GLP-1: Hoping To Change Things Up In The Weight-Management Space

Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting

Here are the major earnings after the close today

The Company continues to expect revenue in the range of $200 million to $210 million in fiscal year 2025, adjusted EBITDA of $18 million to $21 mil...

LifeVantage sees QFY25 EPS 70c-80c, consensus 72c

Reports Q1 revenue $47.2M, consensus $49.8M."It's an incredible time to be at LifeVantage (LFVN) as we just launched the MindBody GLP-1 System(TM),...

LifeVantage reports Q1 EPS 15c, one-estimate 15c

LifeVantage declares $0.04 dividend

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a 140%...

LifeVantage announces results from MindBody GLP-1 System trial

LifeVantage Corporation (LFVN) Q1 2025 Earnings Call Transcript

LifeVantage Corp ( ($LFVN) ) has realeased its Q1 earnings. Here is a breakdown of the information LifeVantage Corp presented to its investors. Lif...

LifeVantage Reports Q1 Fiscal 2025 Financial Results

AAPL

ALSN

AMZN

APAM

ATGE

ATOM

BGFV

BMEA

BMRN

BRSP

CAKE

CHCT

CHTR

CTRE

DASH

ENVX

EXEL

EXLS

FFIV

FSLR

FVRR

GOOG

HRZN

HSBC

IDCC

ILPT

INTC

INUV

JBGS

LBTYA

LBTYK

LFUS

LMND

LSTR

LYSCF

MDLZ

MFIN

MGPI

MRNS

MSFT

MTEX

NATR

OSTX

PAPL

PHUN

PILBF

PRTS

PTON

QRVO

RDDT

RKLB

RMBS

RMLFF

SABR

SAGE

SAVE

SBUX

SNAP

STAG

SVCO

TLTFF

TRTX

TUPBQ

UBER

USNA

VRNS

WERN

WHLR

XPEV

Press Releases

LifeVantage Announces Positive In Vitro Results for New GLP-1 System Showing Synergistic Gene Activation for Enhanced Weight Management* †

LifeVantage Completes Successful Human Clinical Trial with New GLP-1 System for Activated Weight Loss* †

LifeVantage Announces Update to Evolve Compensation Plan with New Sharing Bonus

Health Care

LifeVantage Introduces the MindBody GLP-1 System™ Transforming Weight Management into a Sustainable Lifestyle

LifeVantage to Announce First Quarter Fiscal Year 2025 Results on October 29, 2024

LifeVantage to Participate at the LD Micro Main Event XVII

LifeVantage Reports Full Clinical Results Including Average of 140% Increase in GLP-1 with the MindBody GLP-1 System™Ω

Dividends

LifeVantage Declares Quarterly Dividend

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025

LifeVantage to Participate at the Sidoti Micro Cap Conference

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

The Beauty Health Company - Class A Common Stock

Beauty Health

Synergy CHC

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Comments

Lifevantage

Vendite allo scoperto

Lifevantage (NASDAQ:LFVN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO